Microsomal Prostaglandin E Synthase Inhibition in Inflammatory Disorders

Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme that catalyses the conversion of cyclooxygenase-derived prostaglandin H₂ into pro-inflammatory prostaglandin E₂ (PGE₂). Unlike broad cyclooxygenase inhibitors, selective suppression of mPGES-1 offers the potential to dampen inflammatory responses while preserving protective prostanoids. Research over the past two decades has elucidated the role of mPGES-1 in a spectrum of pathological conditions, including rheumatoid arthritis, cardiovascular injury, postoperative pain and certain cancers. Inhibition of mPGES-1 has been shown to reduce PGE₂-driven vasodilation, leukocyte recruitment and nociceptive sensitisation, with fewer gastrointestinal and cardiovascular side effects than traditional nonsteroidal anti-inflammatory drugs. Advances in structural biology, animal models and early clinical evaluation have converged to position mPGES-1 inhibitors as promising next-generation anti-inflammatory agents.

Research from Nature Portfolio

Analgesic efficacy of highly selective mPGES-1 inhibition has been demonstrated in models of postoperative pain, revealing potent relief of acute and chronic pain states without respiratory depression or addiction risk. Optimised compounds displayed favourable oral bioavailability and robust blockade of PGE₂ overproduction in target tissues. Structure-based design studies further identified dual-species inhibitors effective against both human and rodent mPGES-1, enabling translation into wild-type mouse models. These compounds significantly reduced inflammatory markers and oedema in vivo, outperforming established cyclooxygenase-2 inhibitors. In cardiovascular research, deletion of mPGES-1 in murine models of myocardial ischaemia–reperfusion injury uncovered a protective role for endothelial PGE₂ signalling via the EP4 receptor, constraining microvascular dysfunction and inflammatory cell infiltration. Administration of a PGE analogue restored perfusion in mPGES-1-deficient hearts, underscoring the nuanced interplay between enzyme inhibition and receptor-mediated cytoprotection.

Microsomal Prostaglandin E Synthase Inhibition in Inflammatory Disorders publication trend

The graph below shows the total number of articles in microsomal prostaglandin e synthase inhibition in inflammatory disorders across all publications each year (not limited to Nature Index journals).

Technical terms

mPGES-1: An inducible membrane-associated enzyme converting prostaglandin H₂ into prostaglandin E₂ during inflammatory responses.

Prostaglandin E₂ (PGE₂): A bioactive lipid mediator that promotes vasodilation, pain sensitisation and immune cell activation.

Cyclooxygenase (COX): Enzymes (COX-1/COX-2) that catalyse the initial conversion of arachidonic acid to prostaglandin H₂.

EP4 receptor: A G-protein-coupled receptor subtype that mediates many of the vascular and anti-inflammatory effects of PGE₂.

IC₅₀: The concentration of an inhibitor required to reduce an enzyme’s activity by 50%, indicating potency.

References

1. Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2*. Journal of Biological Chemistry (2000).
2. Analgesic effects of a highly selective mPGES-1 inhibitor. Scientific Reports (2023).
3. The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury. Nature Communications (2019).
4. Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type mice as a new generation of anti-inflammatory drugs. Scientific Reports (2018).
5. Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition. European Journal of Medicinal Chemistry (2025).
6. mPGES-1 Inhibitor Discovery Based on Computer-Aided Screening: Pharmacophore Models, Molecular Docking, ADMET, and MD Simulations. Molecules (2023).
7. The anti-inflammatory and vasoprotective properties of mPGES-1 inhibition offer promising therapeutic potential. Expert Opinion on Therapeutic Targets (2023).